drugset / Trial / NCT05630846

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846

Phase 2 Completed 801 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.

Timeline

Start
2022-12-14
Primary completion
2024-06-07
Completion
2024-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject M(L)M(L)R(L)V(L)NS Unknown Subcutaneous
Subject MM(H)RVNS Unknown Subcutaneous
Subject MMRV(H)NS Unknown Subcutaneous
Comparator ProQuad Vaccine Subcutaneous

Indications